Condition: Stroke (CVA) or TIA · Carotid Artery Plaque · Atherosclerosis Cardiovascular Disease · Sponsor: Universitaire Ziekenhuizen KU Leuven
This clinical trial aims to evaluate whether \[¹⁸F\]AlF-OC PET/MRI can characterize and quantify inflammation in carotid atherosclerotic plaques. The study will assess if tracer uptake in culprit and non-culprit carotid arteries, measured by standardized uptake values (SUV), is associated with future cerebrovascular events. Specifically, it will examine whether \[¹⁸F\]AlF-OC uptake predicts the risk of recurrent ipsilateral TIA, amaurosis fugax, stroke, or other vascular complications. Participants will undergo \[¹⁸F\]AlF-OC PET/MRI and will be followed via telephone interviews at 90 days, 1 year, and 3 years after their initial stroke or TIA.
This description comes directly from the study's public registry record.
Robin Lemmens, MD PhD · +32 16 34 42 80 · robin.lemmens@uzleuven.be
Louise Maes, MD · +32 16 34 42 80 · louise.maes@uzleuven.be
Always discuss trial participation with your own doctor first.
| UZ Leuven | Leuven, Vlaams-Brabant, Belgium | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07104487